Aytu BioPharma, Inc.AYTUNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -13.48% | +31.57% | -15.80% | -16.21% | -6.51% |
| Gross Profit Growth | -26.14% | +23.60% | -13.88% | -23.35% | -15.65% |
| EBITDA Growth | -40.89% | +489.93% | +0.00% | -16.20% | -446.96% |
| Operating Income Growth | -153.88% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +33.31% | -1443.15% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +5.00% | -5350.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -148.31% | +0.00% |
| Weighted Average Shares Growth | +11.13% | +10.93% | +22.64% | +28.10% | +63.67% |
| Weighted Average Shares Diluted Growth | +53.78% | +48.36% | +22.64% | +114.04% | +18.28% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +26.51% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +26.18% |
| Receivables Growth | -13.60% | +19.72% | +32.43% | +43.46% | +21.73% |
| Inventory Growth | -14.74% | -16.18% | -5.82% | -13.96% | -21.91% |
| Asset Growth | -11.45% | -3.62% | +4.48% | +7.91% | +4.97% |
| Book Value per Share Growth | -15.74% | +2.21% | -44.20% | -39.35% | -71.80% |
| Debt Growth | -6.12% | +0.08% | +39.71% | +49.45% | +34.62% |
| R&D Expense Growth | +0.19% | -73.49% | -79.31% | -100.00% | -100.00% |
| SG&A Expenses Growth | -2.96% | -8.64% | -23.55% | -4.99% | +13.86% |